<code id='2422CEA236'></code><style id='2422CEA236'></style>
    • <acronym id='2422CEA236'></acronym>
      <center id='2422CEA236'><center id='2422CEA236'><tfoot id='2422CEA236'></tfoot></center><abbr id='2422CEA236'><dir id='2422CEA236'><tfoot id='2422CEA236'></tfoot><noframes id='2422CEA236'>

    • <optgroup id='2422CEA236'><strike id='2422CEA236'><sup id='2422CEA236'></sup></strike><code id='2422CEA236'></code></optgroup>
        1. <b id='2422CEA236'><label id='2422CEA236'><select id='2422CEA236'><dt id='2422CEA236'><span id='2422CEA236'></span></dt></select></label></b><u id='2422CEA236'></u>
          <i id='2422CEA236'><strike id='2422CEA236'><tt id='2422CEA236'><pre id='2422CEA236'></pre></tt></strike></i>

          entertainment

          entertainment

          author:hotspot    Page View:85
          Adam's take main illustration
          Molly Ferguson/STAT

          Anavex Life Sciences is in a tough spot. The serial dissembler of clinical trial results might be forced, finally, to tell the truth when it reads out its next study in Rett syndrome.

          What sets Anavex apart from all the other biotechs on my radar screen is its habit of shifting the goalposts on clinical trials. Twice last year, first in February and then in December, Anavex announced “positive” outcomes from studies of its drug called blarcamesine — except the results were derived from efficacy endpoints that were not part of the original study designs.

          advertisement

          If blarcamesine fails to achieve the pre-determined goals of clinical trials, the thinking apparently goes, then just make a post-hoc change to the study goals.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          Medicare proposal to cover medical devices draws a mixed reaction
          Medicare proposal to cover medical devices draws a mixed reaction

          AdobeThemedicaldeviceindustryissplitonwhetheraproposednewMedicarereimbursementpathwaywilldoanythingt

          read more
          The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies
          The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

          BiogenCEOChristopherViehbacherSTATTwoyearsafterabigscientificswingnearlypushedBiogentothebrink,CEOCh

          read more
          Medical records are filled with copy
          Medical records are filled with copy

          AdobeIrecentlytookcareofapatientwhosemedicalrecordsincludedmultiplenotesaboutherpastopen-heartsurger

          read more

          Obamacare plans could cover weight loss drugs

          CarstenSnejbjerg/BloombergYou’rereadingthewebeditionofD.C.Diagnosis,STAT’stwice-weeklynewsletterabou